BCLP Advises Lenders in Acquisition of LCV Laboratories by Bioclinic

The international law firm BCLP advised Credit Lyonnais (LCL) in the financing of the acquisition of LCV laboratories by Bioclinic. 

After the acquisition of Biomega in the spring of 2020, the Bioclinic group signed a new build-up with the acquisition of LCV Laboratories, a medical biology operator in the Val-de-Marne and Essonne departments. The transaction valued at more than €30 million. 

This acquisition, carried out over the counter within a very short timeframe, was partly financed by senior debt led by LCL with Erik Pebreuil and a banking pool comprising LCL, Banque Neuflize OBC, BNP Paribas, Caisse d'Epargne Ile-de-France, Société Générale, Zencap Asset Management and Schelcher Prince Gestion, and by mezzanine debt with Bioclinic’s historical financial investors (Andera Partners, Idia Capital Investissement, Amundi Private Equity Funds (PEF) and Socadif).

BCLP’s Paris-based team, led by Partner Olivier Borenstejn and Associate Emmanuel Le Galloc’h, acted on behalf of the banking pool for the financing aspects.